Residency · Residency · Vascular Surgery
Abdominal Aortic Aneurysm: Pathophysiology, Screening, and Surveillance
Overview
An abdominal aortic aneurysm (AAA) is characterized by a focal dilation of the abdominal aorta measuring 3.0 cm or greater, or more than 50% enlargement compared to the normal aortic diameter. Typically, the infrarenal aorta has a diameter of about 2.0 cm, although this varies depending on age, sex, and body size. The prevalence of AAA ranges from 4 to 8% in men over 65 years old and 0.5 to 1.5% in women over 65. Rupture of an AAA is a significant cause of mortality, ranking as the 13th leading cause of death in the United States. The overall mortality rate from ruptured AAA is extremely high, between 65 and 85%, which includes deaths occurring before hospital arrival.
Pathophysiology
Structural Degeneration
The pathogenesis of AAA involves progressive structural degeneration of the aortic wall, primarily driven by matrix metalloproteinases (MMPs), especially MMP-2 and MMP-9. These enzymes degrade key components of the aortic media and adventitia, such as elastin and collagen. Normally, the activity of MMPs is balanced by tissue inhibitors of metalloproteinases (TIMPs), but in AAA this balance is disrupted, leading to excessive matrix breakdown. Elastin fragmentation results in the loss of elastic lamellae within the media, reducing wall compliance and promoting progressive dilation. Collagen remodeling initially acts as a compensatory mechanism to maintain wall integrity but eventually fails, contributing to aneurysm rupture. Additionally, apoptosis of smooth muscle cells causes thinning of the medial layer, further weakening the vessel wall.
Inflammatory Component
Chronic transmural inflammation is a hallmark of AAA, characterized by infiltration of macrophages, which are the primary source of MMPs, as well as T and B lymphocytes and mast cells. These inflammatory cells release cytokines such as interleukin-1 (IL-1), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-alpha), which promote MMP activation and perpetuate tissue degradation. Adventitial neovascularization also occurs, contributing to the inflammatory milieu. A subset of AAAs, known as inflammatory AAAs, display an intense inflammatory response with a thick fibrotic rind and perianeurysmal fibrosis.
Biomechanical Factors
Biomechanical stress plays a critical role in AAA progression. According to Laplace's law, wall tension is proportional to the product of pressure and radius divided by twice the wall thickness. As the aneurysm enlarges, the radius increases, thereby elevating wall tension and creating a self-reinforcing cycle that predisposes to rupture when wall stress surpasses wall strength. The presence of an intraluminal thrombus has a debated role; it may reduce wall stress by acting as a cushion, but it can also weaken the wall by inducing a hypoxic environment that promotes inflammation.
Hemodynamic Factors
The infrarenal aorta is particularly susceptible to disturbed blood flow due to reflected pressure waves from the iliac bifurcation. This segment also has fewer vasa vasorum compared to the suprarenal aorta, which may contribute to wall hypoxia. Oscillatory shear stress in this region promotes endothelial dysfunction, further contributing to aneurysm formation and progression.
<image>Histological comparison of a normal aortic wall versus an aneurysmal aortic wall, showing elastin fragmentation, smooth muscle cell loss, inflammatory cell infiltration, and MMP-mediated matrix degradation in the aneurysmal specimen</image>
Risk Factors
Non-Modifiable
Age over 65 years is the strongest demographic risk factor for AAA. Male sex confers a 4 to 6 times higher prevalence compared to females. White individuals have a higher prevalence than Black, Hispanic, or Asian populations. A positive family history significantly increases risk; having a first-degree relative with AAA raises the risk by 2 to 4 times, and 15 to 25% of patients with AAA report such a family history.
Modifiable
Smoking is the most important modifiable risk factor for AAA. The risk increases with cumulative exposure measured in pack-years and persists for years after cessation. Smoking also accelerates aneurysm growth. Hypertension contributes to increased wall stress but is less strongly associated with AAA formation than smoking. Hyperlipidemia is linked to atherosclerosis, which is distinct from the pathophysiology of AAA but often coexists.
Protective Factors
Interestingly, diabetes mellitus is paradoxically associated with a lower prevalence of AAA and slower aneurysm growth. Potential mechanisms include the stiffening of the aortic wall by advanced glycation end-products and possible anti-inflammatory effects of metformin. Female sex may also be protective due to estrogen, although women tend to rupture at smaller aneurysm diameters.
Screening
USPSTF Recommendations (2019 Update)
The United States Preventive Services Task Force (USPSTF) recommends a one-time screening abdominal ultrasound for men aged 65 to 75 who have ever smoked, classified as a Grade B recommendation. For men in the same age range who have never smoked, screening is a Grade C recommendation and should be individualized based on other risk factors. For women aged 65 to 75 who have ever smoked or have a family history of AAA, the evidence is insufficient (Grade I), and screening decisions should be individualized. Women who have never smoked are not recommended for screening.
SVS Recommendations
The Society for Vascular Surgery (SVS) advocates for more aggressive screening, recommending a one-time ultrasound for all men and women aged 65 to 75 with a smoking history, as well as men and women aged 55 and older with a family history of AAA.
Screening Efficacy
Large trials such as the MASS, Chichester, and Viborg studies have demonstrated that screening reduces AAA-related mortality by 40 to 50%. Approximately 300 individuals need to be screened over 10 years to prevent one AAA-related death. Although older trials did not show a significant impact on all-cause mortality, contemporary data suggest evolving benefits. Screening is cost-effective, particularly in populations with higher AAA prevalence.
<image>Ultrasound image of an abdominal aortic aneurysm showing anteroposterior diameter measurement of 4.5 cm with intraluminal thrombus, demonstrating proper technique for screening measurement from outer wall to outer wall</image>
Surveillance
Guidelines Based on AAA Diameter
Surveillance intervals depend on aneurysm size. For ectatic aortas measuring 2.5 to 2.9 cm, some guidelines recommend no further screening, while others suggest surveillance every 10 years. Small AAAs (3.0 to 3.9 cm) are monitored every three years according to SVS guidelines, with some recommending annual follow-up, alongside risk factor modification. AAAs measuring 4.0 to 4.9 cm warrant annual surveillance. When the diameter reaches 5.0 to 5.4 cm, surveillance intervals shorten to every six months as the aneurysm approaches the repair threshold. Elective repair is generally considered at diameters of 5.5 cm or greater in men and 5.0 cm or greater in women, reflecting the higher rupture risk in females.
Growth Rate
Small AAAs typically grow at an average rate of 2 to 3 mm per year, but growth is nonlinear, with larger aneurysms expanding more rapidly. Rapid growth, defined as more than 1 cm per year, is an indication for repair regardless of absolute size. Smoking cessation is the only intervention proven to slow aneurysm growth. No pharmacologic therapies, including doxycycline (an MMP inhibitor), statins, ACE inhibitors, or beta-blockers, have demonstrated efficacy in slowing AAA progression in clinical trials.
Rupture Risk by Diameter
The annual risk of rupture correlates strongly with aneurysm size. AAAs less than 4.0 cm have an almost negligible rupture risk. For aneurysms measuring 4.0 to 4.9 cm, the risk is approximately 0.5 to 1%. This risk increases to 3 to 5% for diameters of 5.0 to 5.9 cm, 10 to 20% for 6.0 to 6.9 cm, 20 to 40% for 7.0 to 7.9 cm, and 30 to 50% for aneurysms 8.0 cm or larger.
| AAA Diameter (cm) | Annual Rupture Risk | Surveillance Interval | Action |
|---|---|---|---|
| 2.5–2.9 (ectatic) | Negligible | Every 10 years (or none) | Risk factor modification |
| 3.0–3.9 | Negligible | Every 3 years | Risk factor modification |
| 4.0–4.9 | 0.5–1% | Annually | Surveillance; consider referral |
| 5.0–5.4 | 3–5% | Every 6 months | Approaching repair threshold |
| 5.5+ (men) / 5.0+ (women) | 3–5%+ | — | Elective repair indicated |
| 6.0–6.9 | 10–20% | — | Repair recommended |
| 7.0–7.9 | 20–40% | — | Urgent repair |
| ≥8.0 | 30–50% | — | Urgent repair |
When to Repair
Elective repair is generally recommended for men with AAAs measuring 5.5 cm or larger and for women at 5.0 cm or larger, reflecting their higher rupture risk at smaller sizes. Repair is also indicated for aneurysms exhibiting rapid growth exceeding 1 cm per year, symptomatic AAAs presenting with pain, tenderness, or distal embolization, and saccular aneurysms, which carry a higher rupture risk and may warrant earlier intervention. Landmark trials such as the UK Small Aneurysm Trial and the ADAM trial have shown no benefit of early repair for AAAs between 4.0 and 5.4 cm compared to surveillance.
Special Considerations
Women and AAA
Although women have a lower prevalence of AAA, they face a higher rupture risk at any given aneurysm diameter and tend to rupture at smaller sizes. Consequently, the repair threshold is lower for women. They also experience worse operative outcomes due to smaller vessels and more complex anatomy. Women are often underscreened, which may contribute to these disparities.
Inflammatory AAA
Inflammatory AAAs account for 5 to 10% of all cases and are characterized by a thick fibrotic rind surrounding the aorta. Perianeurysmal fibrosis can involve adjacent structures such as the ureters, leading to hydronephrosis, as well as the duodenum or inferior vena cava. Laboratory findings often include elevated erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP). Computed tomography typically reveals a characteristic soft tissue "rind" around the aneurysm. Treatment involves standard surgical repair, after which the fibrosis often resolves.
Familial AAA
First-degree relatives of patients with AAA should undergo screening earlier than the general population, typically starting at age 55 if there is a positive family history. The genetic basis of familial AAA is polygenic, with no single gene identified, in contrast to syndromic conditions like Marfan or Ehlers-Danlos syndromes.
<image>CT angiography 3D reconstruction of an infrarenal abdominal aortic aneurysm showing the relationship to the renal arteries, iliac bifurcation, and the aneurysm neck anatomy relevant to surgical planning, with diameter measurements annotated</image>
Clinical Pearls
The most important screening test for AAA is a simple abdominal ultrasound, which requires only about five minutes and has been shown to save lives. Smoking is both the most significant risk factor for AAA development and the only modifiable factor proven to slow aneurysm growth, making smoking cessation counseling essential at every clinical encounter. Women rupture at smaller aneurysm diameters, so the standard 5.5 cm repair threshold should not be applied to them. In the emergency department, a tender AAA should be considered ruptured or symptomatic until proven otherwise, representing a surgical emergency. Currently, no pharmacologic agents have been proven to slow AAA growth, although this remains an active area of research. Diabetes appears paradoxically protective against AAA, and understanding the mechanisms behind this may offer therapeutic insights. Finally, screening programs are cost-effective and have been demonstrated to reduce AAA-related mortality.
References
- Chaikof EL, et al. The Society for Vascular Surgery practice guidelines on the care of patients with an abdominal aortic aneurysm. J Vasc Surg. 2018;67(1):2-77.
- Wanhainen A, et al. European Society for Vascular Surgery (ESVS) 2019 Clinical Practice Guidelines on the Management of Abdominal Aorto-iliac Artery Aneurysms. Eur J Vasc Endovasc Surg. 2019;57(1):8-93.
- UKSAT Participants. Long-term outcomes of immediate repair compared with surveillance of small abdominal aortic aneurysms. N Engl J Med. 2002;346(19):1445-1452.
- Lederle FA, et al. Immediate repair compared with surveillance of small abdominal aortic aneurysms (ADAM trial). N Engl J Med. 2002;346(19):1437-1444.
- Thompson SG, et al. Screening for abdominal aortic aneurysms: the Multicentre Aneurysm Screening Study (MASS). Lancet. 2002;360(9345):1531-1539.
